Depletion of gut microbiota is associated with improved neurologic outcome following traumatic brain injury
No pharmaceutical company has funded the human clinical trials required for FDA approval
When it was recognized that pellagra, a condition marked by diarrhea, dermatitis, dementia, and mortality, could be treated with foods containing NAD+ precursors, particularly vitamin B3, the clinical significance of maintaining NAD+ levels was established in the early 1900s (9). Notably, the skin does not flush with NAD+ injection, in contrast to vitamin B3 (niacin) intake, which also causes this negative effect (10). Low NAD+ levels have recently been associated with a variety of age-related ailments and diseases linked to increased oxidative/free radical damage, including diabetes, heart disease, vascular dysfunction, ischemic brain injury, Alzheimers disease, and vision loss (8, 11-17)
Farsi, F., Mohammadshahi, M., Alavinejad, P., Rezazadeh, A., Zarei, M., & Engali, K
combined use is speculative and may compound adverse metabolic and gastrointestinal effects with no safety framework to guide dosing
